- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | STRYKER CORP - 10-Q, Quarterly Report | 4 | SEC Filings | ||
| Fr | Wolfe Research raises Stryker stock price target on strong Q2 results | 48 | Investing.com | ||
| Fr | Stryker wächst - neue Jahresprognose enttäuscht | 88 | ECOreporter | ||
| Fr | Stryker expects 8.3%-9.3% organic sales growth and $14.95-$15.10 adjusted EPS in 2026 as it resumes share repurchases | 35 | Seeking Alpha | ||
| STRYKER CORPORATION CDR Aktie jetzt für 0€ handeln | |||||
| Fr | Stryker falls despite Q2 beats | 42 | Seeking Alpha | ||
| Do | Stryker Aktie bricht nach verengter Jahresprognose ein | 74 | Investing.com Deutsch | ||
| Do | Stryker Corp. Bottom Line Rises In Q2 | 427 | AFX News | WASHINGTON (dpa-AFX) - Stryker Corp. (SYK) revealed a profit for its second quarter that Increases, from the same period last yearThe company's bottom line came in at $1.276 billion, or $3.30... ► Artikel lesen | |
| Do | Earnings-Movers: Monolithic Power springt zweistellig - Stryker bricht ein | 32 | stock3.com | ||
| Do | Stryker posts Q2 beats, narrows guidance after progress on cyberattack recovery | 12 | MassDevice | ||
| Do | STRYKER: Nach Cyberangriff wächst der Konzern in beiden Sparten | 52 | stock3.com | ||
| Do | Stryker Corporation: Stryker reports second quarter 2026 operating results | 402 | GlobeNewswire (Europe) | Portage, Michigan, July 30, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the second quarter of 2026: Second Quarter Results Reported net sales increased 9.4% to $6.6... ► Artikel lesen | |
| Do | STRYKER CORP - 8-K, Current Report | 8 | SEC Filings | ||
| Di | UBS reiterates Stryker stock Buy rating with $400 price target | 33 | Investing.com | ||
| 16.07. | Stryker fully launches Mako robotic power system for knee surgery in US | 45 | MassDevice | ||
| 16.07. | Stryker launches Mako RPS handheld robotic knee system in U.S. | 7 | Investing.com | ||
| 13.07. | Piper Sandler reiterates Stryker stock rating on Mako strength | 104 | Investing.com | ||
| 13.07. | Piper Sandler bestätigt Stryker-Rating dank starker Nachfrage nach Mako-System | 79 | Investing.com Deutsch | ||
| 09.07. | Stryker's Quarterly Earnings Preview: What You Need to Know | 26 | Barchart.com | ||
| 02.07. | Night Watch Investment Management adds Stryker, Adyen; trims WDC, SIMO among Q2 moves | 21 | Seeking Alpha | ||
| 30.06. | If You Invested $1000 In Stryker Stock 20 Years Ago, You Would Have This Much Today | 16 | Benzinga.com |
1 2 3 4 5 Weiter >>
182 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| APOGEE THERAPEUTICS | 134,07 | -0,01 % | AbbVie trims 2026 profit forecast on Apogee buy, beats second-quarter estimates | ||
| KINIKSA PHARMACEUTICALS | 74,34 | 0,00 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution | - ARCALYST (rilonacept) Q2 2026 net product revenue of $243.6 million, representing ~55% year-over-year growth -- ARCALYST 2026 expected net product revenue increased to $980 - $995 million -- KPL-387... ► Artikel lesen | |
| QIAGEN | 35,720 | -0,75 % | PTA-PVR: QIAGEN N.V.: Veröffentlichung nach § 40 Abs. 1 WpHG | DJ PTA-PVR: QIAGEN N.V.: Veröffentlichung nach § 40 Abs. 1 WpHG
Veröffentlichung gem. -- 40 Abs. 1 WpHG
QIAGEN N.V.: Veröffentlichung nach -- 40 Abs. 1 WpHG
Venlo (pta000/29.07.2026/22:05... ► Artikel lesen | |
| MONTE ROSA THERAPEUTICS | 16,520 | 0,00 % | Monte Rosa, BioAge plunge as Novo's setback casts a shadow over pipeline | ||
| EDGEWISE THERAPEUTICS | 38,430 | 0,00 % | Servier completes the acquisition of Edgewise Therapeutics' Muscular Dystrophy Business | Acquisition supports Servier's strategic ambition in rare neurology with sevasemten, a late-stage investigational treatment for Becker and Duchenne muscular dystrophies. The acquired asset... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 307,93 | +0,03 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026 | ||
| COGENT BIOSCIENCES | 38,910 | -0,05 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen | |
| TRAVERE THERAPEUTICS | 55,89 | 0,00 % | Everest Medicines Limited: Everest Medicines Announces Close of Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib | HONG KONG, July 8, 2026 - (ACN Newswire) - Everest Medicines (HKEX 1952.HK) announced the closing of its previously announced exclusive licensing and collaboration agreement with Travere Therapeutics... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 13,030 | +0,08 % | Summit Therapeutics Flags Going Concern Risk Over Cash Needs | ||
| DYNE THERAPEUTICS | 25,180 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights | - Biologics License Application (BLA) for z-rostudirsen in exon 51 DMD accepted for review by FDA; Priority Review granted; PDUFA target action date set for January 21, 2027 - - Completed enrollment... ► Artikel lesen | |
| ARRIVENT BIOPHARMA | 29,820 | 0,00 % | ArriVent BioPharma, Inc.: ArriVent BioPharma Reports First Quarter 2026 Financial Results | Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected mid-2026IND clearance of ARR-002, ArriVent's dual-targeting MUC16/NaPi2b tetravalent... ► Artikel lesen | |
| ERASCA | 18,150 | 0,00 % | Erasca, Inc.: Erasca Announces Updated Preliminary Phase 1 Data and Registration-Enabling Plans for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors | At RDE of 32 mg QD, encouraging monotherapy responses with 57% uORR in 2L+ KRAS G12X pancreatic cancer in U.S. trial and median relative dose intensity of 100% Monotherapy has been generally well-tolerated... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 103,39 | -0,01 % | Kymera International Appoints Willson Ropp as Chief Executive Officer | Experienced specialty materials executive brings more than 30 years of leadership experience across global manufacturing, operational excellence, business integration, and long-term value... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 20,330 | +0,10 % | Biotech Stocks At 52-Week Highs - LH Rises With Genetic Testing Launch, DYN, SNDA, SLN, AMLX, | LONDON (dpa-AFX) - The following biotech stocks reached a 52-week high on July 27, 2026, driven by key catalysts including prospective clinical trial results, and the launch of new services.Dyne... ► Artikel lesen | |
| TANGO THERAPEUTICS | 27,195 | +0,06 % | Krebs-Blockbuster-Medikament: Revolution Medicines: Auch Europa will das Medikament so schnell wie möglich! | © Foto: KI-generiert mit DALL-ENach starken Studiendaten aus den USA will nach der FDA auch Europas Arzneimittelbehörde das Medikament so schnell wie möglich zulassen. Revolution Medicines wird immer... ► Artikel lesen |
Das Unternehmen STRYKER CORPORATION CDR kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -8,33 % bei einem Aktienkurs von 13,200 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu STRYKER CORPORATION CDR finden Sie auf Wallstreet Online.